{
  "id": "IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition-BBDL",
  "type": "transaction",
  "resourceType": "Bundle",
  "entry": [
    {
      "resource": {
        "resourceType": "MedicinalProductDefinition",
        "id": "IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition",
        "meta": {
          "versionId": "1",
          "lastUpdated": "2022-10-13T16:45:10.176+00:00"
        },
        "extension": [
          {
            "url": "http://ema.europa.eu/fhir/extension/authorisedDoseForm",
            "valueCoding": {
              "system": "http://spor.ema.europa.eu/v1/lists/200000000004",
              "code": "100000073665",
              "display": "Film-coated tablet"
            }
          }
        ],
        "identifier": [
          {
            "system": "http://ema.europa.eu/fhir/mpId",
            "value": "SE-100000848-00051919"
          },
          {
            "system": "http://ema.europa.eu/fhir/eurdId",
            "value": "1725"
          }
        ],
        "domain": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/100000000004",
              "code": "100000000012",
              "display": "Human use"
            }
          ]
        },
        "status": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/200000005003",
              "code": "200000005004",
              "display": "Current"
            }
          ]
        },
        "indication": "Imatinib Sandoz \u00e4r indicerat f\u00f6r behandling av \u2022 vuxna och barn med nydiagnostiserad Philadelphiakromosom (bcr-abl) positiv (Ph+) kronisk myeloisk leukemi (KML), f\u00f6r vilka benm\u00e4rgstransplantation inte \u00e4r en f\u00f6rstahandsbehandling. \u2022 vuxna och barn med Ph+ KML i kronisk fas efter terapisvikt med interferon alfa-behandling, eller i accelererad fas eller blastkris. \u2022 vuxna och barn med nyligen diagnosticerad Philadelphia-kromosom-positiv akut lymfoblastisk leukemi (Ph+ ALL) tillsammans med kemoterapi. \u2022 vuxna patienter med recidiverande eller refrakt\u00e4r Ph+ ALL som monoterapi. \u2022 vuxna patienter med myelodysplastiska/myeloproliferativa sjukdomar (MDS/MPD) f\u00f6renat med rearrangemang av platelet-derived growth factor receptor (PDGFR) -genen. \u2022 vuxna patienter med avancerat hypereosinofilt syndrom (HES) och/eller kronisk eosinofil leukemi (CEL) med FIP1L1-PDGFR\u03b1-rearrangemang. Effekten av imatinib p\u00e5 utfallet av benm\u00e4rgstransplantation har inte unders\u00f6kts.   Imatinib Sandoz \u00e4r indicerat f\u00f6r \u2022 behandling av vuxna patienter med Kit (CD 117) positiva, icke resecerbara och/eller metastaserande, maligna gastrointestinala stromacellstum\u00f6rer (GIST). \u2022 adjuvant behandling av vuxna patienter som l\u00f6per en signifikant risk f\u00f6r recidiv efter resektion av Kit (CD117) positiv GIST. Patienter som l\u00f6per l\u00e5g eller mycket l\u00e5g risk f\u00f6r \u00e5terfall ska inte f\u00e5 adjuvant behandling. \u2022 behandling av vuxna patienter med icke resecerbara dermatofibrosarkoma protuberans (DFSP) och vuxna patienter med \u00e5terkommande och/eller metastaserande DFSP som \u00e4r ol\u00e4mpliga att operera. Hos vuxna och barn baseras effekten av imatinib p\u00e5 det sammantagna hematologiska och cytogenetiska svaret och progressionsfri \u00f6verlevnad vid KML, p\u00e5 hematologiskt och cytogenetiskt respons vid Ph+ ALL, MDS/MPD, p\u00e5 hematologisk respons vid HES/CEL och p\u00e5 objektiv tum\u00f6rrespons hos vuxna patienter vid icke-resecerbara och/eller metastaserande GIST och DFSP och p\u00e5 \u00e5terfallsfri \u00f6verlevnad vid adjuvant GIST. Erfarenheten av imatinib hos patienter med MDS/MPD f\u00f6renat med rearrangemang PDGFR-genen \u00e4r mycket begr\u00e4nsat (se avsnitt 5.1). F\u00f6rutom vid nyligen diagnostiserad KML i kronisk fas finns det inga kontrollerade studier som visar p\u00e5 en klinisk nytta eller \u00f6kad \u00f6verlevnad f\u00f6r dessa sjukdomar.",
        "legalStatusOfSupply": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/100000072051",
              "code": "100000072084",
              "display": "Medicinal product subject to medical prescription"
            }
          ]
        },
        "classification": [
          {
            "coding": [
              {
                "system": "http://spor.ema.europa.eu/v1/lists/100000116677",
                "code": "100000093533",
                "display": "L01EA01"
              }
            ]
          }
        ],
        "name": [
          {
            "productName": "Imatinib Sandoz 400 mg Filmdragerad tablett",
            "namePart": [
              {
                "part": "Imatinib Sandoz",
                "type": {
                  "coding": [
                    {
                      "system": "http://spor.ema.europa.eu/v1/lists/220000000000",
                      "code": "220000000002",
                      "display": "Invented name part"
                    }
                  ]
                }
              },
              {
                "part": "400 mg",
                "type": {
                  "coding": [
                    {
                      "system": "http://spor.ema.europa.eu/v1/lists/220000000000",
                      "code": "220000000004",
                      "display": "Strength part"
                    }
                  ]
                }
              },
              {
                "part": "Filmdragerad tablett",
                "type": {
                  "coding": [
                    {
                      "system": "http://spor.ema.europa.eu/v1/lists/220000000000",
                      "code": "220000000005",
                      "display": "Pharmaceutical dose form part"
                    }
                  ]
                }
              }
            ],
            "countryLanguage": [
              {
                "country": {
                  "coding": [
                    {
                      "system": "http://spor.ema.europa.eu/v1/lists/100000000002",
                      "code": "100000000535",
                      "display": "Sweden"
                    }
                  ]
                },
                "language": {
                  "coding": [
                    {
                      "system": "http://spor.ema.europa.eu/v1/lists/100000072057",
                      "code": "100000072288",
                      "display": "Swedish"
                    }
                  ]
                }
              }
            ]
          }
        ]
      },
      "request": {
        "method": "PUT",
        "url": "MedicinalProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition"
      },
      "fullUrl": "https://hl7-eu.github.io/unicom-ig/branches/mpd-r4b/MedicinalProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition"
    },
    {
      "resource": {
        "resourceType": "RegulatedAuthorization",
        "id": "IMAsandoz-400mg-Tablet-SE-IS-RegulatedAuthorization",
        "meta": {
          "versionId": "1",
          "lastUpdated": "2022-10-13T16:45:10.216+00:00"
        },
        "identifier": [
          {
            "system": "http://ema.europa.eu/fhir/MarketingAuthorizationNumber",
            "value": "51919"
          }
        ],
        "subject": [
          {
            "reference": "MedicinalProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition"
          }
        ],
        "type": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/220000000060",
              "code": "220000000061",
              "display": "Marketing Authorisation"
            }
          ]
        },
        "region": [
          {
            "coding": [
              {
                "system": "http://spor.ema.europa.eu/v1/lists/100000000002",
                "code": "100000000535",
                "display": "Sweden"
              }
            ]
          }
        ],
        "status": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/100000072049",
              "code": "100000072099",
              "display": "Valid"
            }
          ]
        },
        "statusDate": "2015-12-04",
        "holder": {
          "identifier": {
            "system": "https://spor.ema.europa.eu/v1/locations",
            "value": "LOC-100001468"
          },
          "display": "Sandoz A/S"
        },
        "case": {
          "type": {
            "coding": [
              {
                "system": "http://ema.europa.eu/fhir/authorisationDateType",
                "code": "dateOfFirstAuthorisation",
                "display": "First Authorisation"
              }
            ]
          },
          "dateDateTime": "2015-12-04"
        }
      },
      "request": {
        "method": "PUT",
        "url": "RegulatedAuthorization/IMAsandoz-400mg-Tablet-SE-IS-RegulatedAuthorization"
      },
      "fullUrl": "https://hl7-eu.github.io/unicom-ig/branches/mpd-r4b/RegulatedAuthorization/IMAsandoz-400mg-Tablet-SE-IS-RegulatedAuthorization"
    },
    {
      "resource": {
        "resourceType": "AdministrableProductDefinition",
        "id": "IMAsandoz-400mg-Tablet-SE-IS-AdministrableProductDefinition",
        "meta": {
          "versionId": "1",
          "lastUpdated": "2022-10-13T16:45:10.257+00:00"
        },
        "status": "active",
        "formOf": [
          {
            "reference": "MedicinalProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition"
          }
        ],
        "administrableDoseForm": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/200000000004",
              "code": "100000073665",
              "display": "Film-coated tablet"
            }
          ]
        },
        "producedFrom": [
          {
            "reference": "ManufacturedItemDefinition/IMAsandoz-400mg-Tablet-SE-IS-ManufacturedItemDefinition"
          }
        ],
        "routeOfAdministration": [
          {
            "code": {
              "coding": [
                {
                  "system": "http://spor.ema.europa.eu/v1/lists/100000073345",
                  "code": "100000073619",
                  "display": "Oral use"
                }
              ]
            }
          }
        ]
      },
      "request": {
        "method": "PUT",
        "url": "AdministrableProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-AdministrableProductDefinition"
      },
      "fullUrl": "https://hl7-eu.github.io/unicom-ig/branches/mpd-r4b/AdministrableProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-AdministrableProductDefinition"
    },
    {
      "resource": {
        "resourceType": "Ingredient",
        "id": "IMAsandoz-400mg-Tablet-SE-IS-Ingredient",
        "meta": {
          "versionId": "1",
          "lastUpdated": "2022-10-13T16:45:10.397+00:00"
        },
        "status": "active",
        "for": [
          {
            "reference": "MedicinalProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-MedicinalProductDefinition"
          },
          {
            "reference": "ManufacturedItemDefinition/IMAsandoz-400mg-Tablet-SE-IS-ManufacturedItemDefinition"
          },
          {
            "reference": "AdministrableProductDefinition/IMAsandoz-400mg-Tablet-SE-IS-AdministrableProductDefinition"
          }
        ],
        "role": {
          "coding": [
            {
              "system": "http://spor.ema.europa.eu/v1/lists/100000072050",
              "code": "100000072072",
              "display": "Active"
            }
          ]
        },
        "substance": {
          "code": {
            "concept": {
              "coding": [
                {
                  "system": "http://spor.azure-api.net/sms/api/v2/SubstanceDefinition",
                  "code": "100000091825",
                  "display": "Imatinib mesilate"
                }
              ]
            }
          },
          "strength": [
            {
              "presentationRatio": {
                "numerator": {
                  "value": 478,
                  "_comparator": {
                    "extension": [
                      {
                        "url": "http://ema.europa.eu/fhir/extension/comparator",
                        "valueCoding": {
                          "system": "https://spor.ema.europa.eu/v1/lists/100000000008",
                          "code": "100000000049",
                          "display": "equal to"
                        }
                      }
                    ]
                  },
                  "unit": "milligram(s)",
                  "system": "http://spor.ema.europa.eu/v1/lists/100000110633",
                  "code": "100000110655"
                },
                "denominator": {
                  "value": 1,
                  "unit": "unit(s)",
                  "system": "http://spor.ema.europa.eu/v1/lists/100000110633",
                  "code": "100000110756"
                }
              },
              "referenceStrength": [
                {
                  "substance": {
                    "concept": {
                      "coding": [
                        {
                          "system": "https://spor.ema.europa.eu/v2/SubstanceDefinition",
                          "code": "100000091894",
                          "display": "Imatinib"
                        }
                      ]
                    }
                  },
                  "strengthRatio": {
                    "numerator": {
                      "value": 400,
                      "_comparator": {
                        "extension": [
                          {
                            "url": "http://ema.europa.eu/fhir/extension/comparator",
                            "valueCoding": {
                              "system": "https://spor.ema.europa.eu/v1/lists/100000000008",
                              "code": "100000000049",
                              "display": "equal to"
                            }
                          }
                        ]
                      },
                      "unit": "milligram(s)",
                      "system": "http://spor.ema.europa.eu/v1/lists/100000110633",
                      "code": "100000110655"
                    },
                    "denominator": {
                      "value": 1,
                      "unit": "unit(s)",
                      "system": "http://spor.ema.europa.eu/v1/lists/100000110633",
                      "code": "100000110756"
                    }
                  }
                }
              ]
            }
          ]
        }
      },
      "request": {
        "method": "PUT",
        "url": "Ingredient/IMAsandoz-400mg-Tablet-SE-IS-Ingredient"
      },
      "fullUrl": "https://hl7-eu.github.io/unicom-ig/branches/mpd-r4b/Ingredient/IMAsandoz-400mg-Tablet-SE-IS-Ingredient"
    }
  ]
}